HPHA Stock Overview
A biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Heidelberg Pharma AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.14 |
| 52 Week High | €3.97 |
| 52 Week Low | €2.11 |
| Beta | -0.36 |
| 11 Month Change | -19.25% |
| 3 Month Change | -11.57% |
| 1 Year Change | -21.03% |
| 33 Year Change | -58.04% |
| 5 Year Change | 0% |
| Change since IPO | -95.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| HPHA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.6% | -0.7% | -0.02% |
| 1Y | -21.0% | -17.2% | 8.2% |
Return vs Industry: HPHA underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: HPHA underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| HPHA volatility | |
|---|---|
| HPHA Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: HPHA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: HPHA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 98 | Andreas Pahl | heidelberg-pharma.com |
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors.
Heidelberg Pharma AG Fundamentals Summary
| HPHA fundamental statistics | |
|---|---|
| Market cap | €103.93m |
| Earnings (TTM) | -€18.77m |
| Revenue (TTM) | €8.47m |
12.3x
P/S Ratio-5.5x
P/E RatioIs HPHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HPHA income statement (TTM) | |
|---|---|
| Revenue | €8.47m |
| Cost of Revenue | €1.66m |
| Gross Profit | €6.81m |
| Other Expenses | €25.58m |
| Earnings | -€18.77m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 80.41% |
| Net Profit Margin | -221.51% |
| Debt/Equity Ratio | 0% |
How did HPHA perform over the long term?
See historical performance and comparison